Matrix metalloproteinases as therapeutic targets in cancer

Current Cancer Drug Targets

Volumn 5, Issue 3, 2005, Pages 203-220

  Vihinen, Pia ^a   Ala Aho, Risto ^b   Kähäri, Veli Matti ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Angiogenesis; Cancer; MMP; MMPI; Prognosis; Survival

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; A 177430; ABT 518; AE 941; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BATIMASTAT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CGS 27023A; CYTOTOXIC AGENT; DOXORUBICIN; DOXYCYCLINE HYCLATE; ESTROGEN; FLUOROURACIL; FOLINIC ACID; FYK 1388; GEMCITABINE; HORMONE; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MMI 270B; PACLITAXEL; PLATINUM DERIVATIVE; PRINOMASTAT; PROGESTERONE; RALOXIFENE; REBIMASTAT; RO 28 2653; SMALL INTERFERING RNA; SOLIMASTAT; TANOMASTAT; TEMOZOLOMIDE; TETRACYCLINE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; ZINC;

ANGIOGENESIS; ARTHRALGIA; CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HORMONE SUBSTITUTION; HUMAN; JOINT STIFFNESS; METASTASIS; MUSCULOSKELETAL DISEASE; PHOTOTOXICITY; PROGNOSIS; REVIEW; SIDEROBLASTIC ANEMIA; SKIN TOXICITY; SYSTEMATIC REVIEW; TUMOR CLASSIFICATION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 15244342010     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009053765799     Document Type: Review

References (183)

1. Nagase, H.; Woessner J. F. Jr. Matrix metalloproteinases. J. Biol. Chem. 1999, 274, 21491-21494.
2. Shapiro, S. D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 1998, 10, 602-608.
3. Westermarck, J.; Kähäri, V. -M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13, 781-792.
4. Freije, J. M.; Diez Itza, I.; Balbin, M.; Sanchez, L. M.; Blasco, R.; Tolivia, J.; Lopez-Otin, C. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 1994, 269, 16766-16773.
5. Johansson, N.; Airola, K.; Grénman, R.; Kariniemi, A. L.; Saarialho-Kere, U.; Kähäri, V. -M. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am. J. Pathol. 1997, 151, 499-508.
6. Airola, K.; Johansson, N.; Kariniemi, A. -L.; Kähäri, V. -M.; Saarialho-Kere, U. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J. Invest. Dermatol. 1997, 109, 225-231.
7. Johansson, N.; Vaalamo, M.; Grénman, S.; Hietanen, S.; Klemi, P.; Saarialho-Kere, U.; Kähäri, V. M. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am. J. Pathol. 1999, 154, 469-480.
8. Airola, K.; Karonen, T.; Vaalamo, M.; Lehti, K.; Lohi, J.; Kariniemi, A. L.; Keski-Oja, J.; Saarialho-Kere, U. K. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br. J. Cancer 1999, 80, 733-743.
9. Nikkola, J.; Vihinen, P.; Vlaykova, T.; Hahka-Kemppinen, M.; Kähäri, V. -M.; Pyrhönen, S. High collagenase-1 expression correlates to favourable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res. 2001, 11, 157-166.
10. Uria, J. A.; Balbin, M.; López, J. M.; Alvarez, J.; Vizoso, F.; Takigawa, M.; Lopez-Otin, C. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am. J. Pathol. 1998, 153, 91-101.
11. Boström, P. J.; Ravanti, L.; Reunanen, N.; Aaltonen, V.; Söderström K. O.; Kähäri V. -M.; Laato, M. Expression of collagenase-3 (matrix metalloproteinase-13) in transitional cell carcinoma of the urinary bladder. Int. J. Cancer 2000, 88, 417-423.
12. Basset, P.; Bellocq, J. P.; Wolf, C.; Stoll, I.; Hutin, P.; Limacher, J. M.; Podhajcer, O. L.; Chenard, M. P.; Rio, M. C.; Chambon, P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348, 699-704.
13. Shapiro, S. D.; Kobayashi, D. K.; Ley, T. J. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. 1993, 268, 23824-23829.
14. Kerkelä, E.; Ala-aho, R.; Jeskanen, L.; Rechardt, O.; Grenman, R.; Shapiro, S. D.; Kähäri, V. M.; Saarialho-Kere, U. Expression of human macrophage metalloelastase (MMP-12) by tumor cells in skin cancer. J. Invest. Dermatol. 2000, 114, 1113-1119.
15. Saarialho-Kere, U.; Crouch, E. C.; Parks, W. C. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J. Invest. Dermatol. 1995, 105, 190-196.
16. Wilson, C. L.; Ouellette, A. J.; Satchell, D. P.; Ayabe, T.; Lopez-Boado, Y. S.; Stratman, J. L.; Hultgren, S. J.; Matrisian, L. M.; Parks, W. C. Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999, 286, 113-117.
17. Uria, J. A.; Lopez-Otin, C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 2000, 60, 4745-4751.
18. Seiki, M. Membrane-type matrix metalloproteinases. APMIS 1999, 107, 137-143.
19. Okada, A.; Bellocq, J. P.; Rouyer, N.; Chenard, M. P.; Rio, M. C.; Chambon, P.; Basset, P. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA 1995, 92, 2730-2734.
20. Hieta, N.; Impola, U.; López-Otín, C.; Saarialho-Kere, U.; Kähäri, V. -M. Matrix metalloproteinase-19 expression in cutaneous wound healing and in cultured dermal fibroblasts. J. Invest. Dermatol. 2003, 121, 997-1004.
21. Impola, U.; Toriseva, M.; Suomela, S.; Jeskanen, L.; Hieta, N.; Jahkola, T.; Grénman, R.; Kähäri, V. -M.; Saarialho-Kere, U. MMP-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int. J. Cancer 2003, 103, 709-716.
22. Velasco, G.; Pendás, A. M.; Fueyo, A.; Knäuper, V.; Murphy, G.; López-Otín, C. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 1999, 274, 4570-4576.
23. Westermarck, J.; Seth, A.; Kähäri, V. -M. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997, 14, 2651-2660.
24. Brew, K.; Dinakarpandian, D.; Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000, 1477, 267-283.
25. Kähäri, V. -M.; Saarialho-Kere, U. Matrix metalloproteinases and their inhibitors in tumor growth and invasion. Ann. Med. 1999, 31, 34-45.
26. Oh, J.; Takahashi, R.; Kondo, S.; Mizoguchi, A.; Adachi, E.; Sasahara, R. M.; Nishimura, S.; Imamura, Y.; Khayama, H.; Alexander, D. B.; Ide, C.; Horan, T. P.; Arakawa, T.; Yoshida, H.; Nishikawa, S.; Itoh, Y.; Seiki, M.; Itohara, S.; Takahashi, C.; Noda, M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107, 789-800.
27. Takeuchi, T.; Hisanaga, M.; Nagao, M.; Ikeda, N.; Fujii, H.; Koyama, F.; Mukogawa, T.; Matsumoto, H.; Kondo, S.; Takahashi, C.; Noda, M.; Nakajima, Y. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin. Cancer Res. 2004, 10, 5572-5579.
28. Kuittinen, O.; Soini, Y.; Turpeenniemi-Hujanen, T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur. J. Haematol. 2002, 69, 205-212.
29. Torng, P. L.; Mao, T. L.; Chan, W. Y.; Huang, S. C.; Lin, C. T. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol. Oncol. 2004, 92, 559-567.
30. Ikoma, T.; Takahashi, T.; Nagano, S.; Li, Y. M.; Ohno, Y.; Ando, K.; Fujiwara, T.; Fujiwara, H.; Kosai, K. A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin. Cancer Res. 2004, 10, 1192-1200.
31. Peterson, J. T. Matrix metalloproteinase inhibitor development and the remodelling of drug discovery. Heart failure Rev. 2004, 9, 63-79.
32. Osteen, K. G.; Keller, N. R.; Feltus, F. A.; Melner, M. H. Paracrine regulation of matrix metalloproteinase expression in the normal human endometrium. Gynecol. Obstet. Invest. 1999, 485, 2-13.
33. Parikka, V.; Lehenkari, P.; Sassi, M. L.; Halleen, J.; Risteli, J.; Härkönen, P.; Väänänen, H. K. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinol. 2001, 42, 5371-5378.
34. D'Ascenzo, S.; Giusti, I.; Millimaggi, D.; Marci, R.; Tatone, C.; Cardigno, C. R.; Moscarini, M.; Pavan, A.; Dolo, V.; Caserta, D. Intrafollicular expression of matrix metalloproteinases and their inhibitors in normally ovulating women compared with patients undergoing in vitro fertilization treatment. Eur. J. Endocrinol. 2004, 151, 87-91.
35. Smith, L. M.; Wise, S. C.; Hendricks, D. T.; Sabichi, A. L.; Bos, T.; Reddy, P.; Brown, P. H.; Birrer, M. J. c-Jun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999, 18, 6063-6070.
36. Di Nezza, L.; Jobling, T.; Salamonse, L. A. Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol. Oncol. 2003, 89, 325-333.
37. Stevenson, J. C.; Oladipo, A.; Manassiev, N.; Whitehead, M. I.; Guilford, S.; Proudler, A. J. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br. J. Haematol. 2004, 124, 802-808.
38. Zhang, Y.; Stewart, K. G.; Davidge, S. T. Estrogen replacement reduces age-associated remodeling in rat mesenteric arteries. Hypertension 2000, 36, 970-974.
39. Christodoulakos, G. E.; Panoulis, C. P.; Lambrinoudaki, I. V.; Botsis, D. S.; Dendrinos, S. G.; Economou, E.; Creatsas, G. C. The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women. Menopause 2004, 11, 299-305.
40. Talvensaari-Mattila, A.; Pääkkö, P.; Turpeenniemi-Hujanen, T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res. Treat. 1999, 58, 287-293.
41. Chenard, M. P.; O'Siorain, L.; Shering, S.; Rouyer, N.; Lutz, Y.; Wolf, C.; Basset, P.; Bellocq, J. P.; Duffy, M. J. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer 1996, 69, 448-451.
42. Hirvonen, R.; Talvensaari-Mattila, A.; Paakko, P.; Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res. Treat. 2003, 77, 85-91.
43. Giannelli, G.; Erriquez, R.; Fransvea, E.; Daniele, A.; Trerotoli, P.; Schittulli, F.; Grano, M.; Quaranta, M.; Antonaci, S. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int. J. Cancer 2004, 109, 782-785.
44. La Rocca, G.; Pucci-Minafra, I.; Marrazzo, A.; Taormina, P.; Minafra, S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br. J. Cancer 2004, 90, 1414-1421.
45. Leppä, S.; Saarto, T.; Vehmanen, L.; Blomqvist, C.; Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin. Cancer Res. 2004, 10, 1057-1063.
46. Wilson, M. J.; Woodson, M.; Wiehr, C.; Reddy, A.; Sinha, A. A. Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat. Exp. Mol. Pathol 2004, 77, 7-17.
47. Ross, J. S.; Kaur, P.; Sheehan, C. E.; Fisher, H. A.; Kaufman, R. A. Jr.; Kallakury, B. V. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod. Pathol. 2003, 16, 198-205.
48. Wood, M.; Fudge, K.; Mohler, J. L.; Frost, A. R.; Garcia, F.; Wang, M.; Stearns, M. E. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin. Exp. Metastasis 1997, 15, 246-258.
49. Trudel, D.; Fradet, Y.; Meyer, F.; Harel, F.; Tetu, B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 2003, 63, 8511-8515.
50. Latil, A.; Bieche, I.; Chene, L.; Laurendeau, I.; Berthon, P.; Cussenot, O.; Vidaud, M. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin. Cancer Res. 2003, 9, 5477-5485.
51. Chan, L. W.; Moses, M. A.; Goley, E.; Sproull, M.; Muanza, T.; Coleman, C. N.; Figg, W. D.; Albert, P. S.; Menard, C.; Camphausen, K. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J. Clin. Oncol. 2004, 22, 499-506.
52. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
53. Itoh, T.; Tanioka, M.; Matsuda, H.; Nishimoto, H.; Yoshioka, T.; Suzuki, R.; Uehira, M. Experimental metastasis is suppressed in MMP-9 -deficient mice. Clin. Exp. Metastasis 1999, 17, 177-181.
54. Johnson, C.; Sung, H. J.; Lessner, S. M.; Fini, M. E.; Galis, Z. S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ. Res. 2004, 94, 262-268.
55. Zucker, S.; Vacirca, J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004, 23, 101-117.
56. Bister, V. O.; Salmela, M. T.; Karjalainen-Lindsberg, M. L.; Uria, J.; Lohi, J.; Puolakkainen, P.; Lopez-Otin, C.; Saarialho-Kere, U. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig. Dis. Sci. 2004, 49, 653-661.
57. Chantrain, C. F.; Shimada, H.; Jodele, S.; Groshen, S.; Ye, W.; Shalinsky, D. R.; Werb, Z.; Coussens, L. M.; DeClerck, Y. A. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004, 64, 1675-1686.
58. Passlick, B.; Sienel, W.; Seen-Hibler, R.; Wockel, W.; Thetter, O.; Mutschler, W.; Pantel, K. Overexpression of matrix metalloproteinase 2 predicts unfavourable outcome in early-stage non-small cell lung cancer. Clin. Cancer Res. 2000, 6, 3944-3948.
59. Cox, G.; Jones, J. L.; O'Byrne, K. J. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin. Cancer Res. 2000, 6, 2349-2355.
60. Sienel, W.; Hellers, J.; Morresi-Hauf, A.; Lichtinghagen, R.; Mutschler, W.; Jochum, M.; Klein, C.; Passlick, B.; Pantel, K. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int. J. Cancer 2003, 103, 647-651.
61. Tamura, M.; Oda, M.; Matsumoto, I.; Tsunezuka, Y.; Kawakami, K.; Ohta, Y.; Watanabe, G. The Combination Assay with Circulating Vascular Endothelial Growth Factor (VEGF)-C, Matrix Metalloproteinase-9, and VEGF for Diagnosing Lymph Node Metastasis in Patients With Non-Small Cell Lung Cancer. Ann. Surg. Oncol. 2004, 11, 928-933.
62. Aljada, I. S.; Ramnath, N.; Donohue, K.; Harvey, S.; Brooks, J. J.; Wiseman, S. M.; Khoury T.; Loewen, G; Slocum, H. K.; Anderson, T. M.; Bepler, G.; Tan, D. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 3218-3229.
63. Pozzi, A.; LeVine, W. F.; Gardner, H. A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002, 21, 272-281.
64. Yang, J. C.; Haworth, L.; Sherry, R. M.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Steinberg, S. M.; Chen, H. X.; Rosenberg, S. A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349, 427-434.
65. Cho, N. H.; Shim, H. S.; Rha, S. Y.; Kang, S. H.; Hong, S. H.; Choi, Y. D.; Hong, S. J.; Cho, S. H. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur. Urol. 2003, 44, 560-566.
66. Takahashi, M.; Oka, N.; Naroda, T.; Nishitani, M. A.; Kanda, K.; Kanayama, H. O.; Kagawa S. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int. J. Urol. 2002, 9, 531-538.
67. Kamiya, N.; Kishimoto, T.; Suzuki, H.; Sekita, N.; Nagai, Y.; Oosumi, N.; Kito, H.; Tochigi, N.; Shinbo, M.; Nemori, R.; Ichikawa, T.; Igarashi, T.; Ito, H.; Ishikura, H. Increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion. Int. J. Cancer 2003, 106, 480-485.
68. Zhang, X.; Yamashita, M.; Uetsuki, H.; Kakehi, Y. Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int. J. Urol. 2002, 9, 509-514.
69. Slaton, J. W.; Karashima, T.; Perrotte, P.; Inoue, K.; Kim, S. J.; Izawa, J.; Kedar, D.; McConkey, D. J.; Millikan, R.; Sweeney, P.; Yoshikawa, C.; Shuin, T.; Dinney, C. P. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin. Cancer Res. 2001, 7, 2840-2853.
70. Vasala, K.; Paakko, P.; Turpeenniemi-Hujanen, T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology 2003, 62, 952-957.
71. Gakiopoulou, H.; Nakopoulou, L.; Siatelis, A.; Mavrommatis, I.; Panayotopoulou, E. G.; Tsirmpa, I.; Giannopoulos A. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin. Cancer Res. 2003, 9, 5573-5381.
72. Ito, T.; Ito, M.; Shiozawa, J.; Naito, S.; Kanematsu, T.; Sekine, I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod. Pathol. 1999, 12, 669-674.
73. Yamamoto, H.; Itoh, F.; Iku, S.; Adachi, Y.; Fukushima, H.; Sasaki, S.; Mukaiya, M.; Hirata, K.; Imai, K. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J. Clin. Oncol. 2001, 15, 1118-1127.
74. Harvey, S. R.; Hurd, T. C.; Markus, G.; Martinick, M. I.; Penetrante, R. M.; Tan, D.; Venkataraman, P.; DeSouza, N.; Sait, S. N.; Driscoll, D. L.; Gibbs, J. F. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin. Cancer Res. 2003, 9, 4935-4943.
75. Chung, T. W.; Moon, S. K.; Lee, Y. C.; Kim, J. G.; Ko, J. H.; Kim, C. H. Enhanced expression of matrix metalloproteinase-9 by hepatitis B virus infection in liver cells. Arch. Biochem. Biophys. 2002, 408, 147-154.
76. Lara-Pezzi, E.; Gomez-Gaviro, M. V.; Galvez, B. G.; Mira, E.; Iniguez, M. A.; Fresno, M.; Martinez-A, C.; Arroyo, A. G.; Lopez-Cabrera, M. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J. Clin. Invest. 2002, 110, 1831-1838.
77. Ishii, Y.; Nakasato, Y.; Kobayashi, S.; Yamazaki, Y.; Aoki, T. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2003, 22, 461-470.
78. Yamashita, K.; Mori, M.; Kataoka, A.; Inoue, H.; Sugimachi, K. The clinical significance of MMP-1 expression in eosophageal carcinoma. Br. J. Cancer 2001, 84, 276-282.
79. Yamashita, K.; Mori, M.; Shiraishi, T.; Shibuta, K.; Sugimachi, K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin. Cancer Res. 2000, 6, 1169-1174.
80. Tanioka, Y.; Yoshida, T.; Yagawa, T.; Saiki, Y.; Takeo, S.; Harada, T.; Okazawa, T.; Yanai, H.; Okita, K. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br. J. Cancer 2003, 89, 2116-2121.
81. Etoh, T.; Inoue, H.; Yoshikawa, Y.; Barnard, G. F.; Kitano, S.; Mori, M. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in eosophageal cancer is related to cancer aggressiveness. Gut 2000, 47, 50-56.
82. Yamashita, K.; Tanaka, Y.; Mimori, K.; Inoue, H.; Mori, M. Differential expression of MMP and uPA systems and prognostic relevance of their expression in esophageal squamous cell carcinoma. Int. J. Cancer 2004, 110, 201-207.
83. Ding, Y.; Shimada, Y.; Gorrin-Rivas, M. J.; Itami, A.; Li, Z.; Hong, T.; Maeda, M.; Komoto, I.; Kawabe, A.; Kaganoi, J.; Imamura, M. Clinicopathological significance of human macrophage metalloelastase expression in esophageal squamous cell carcinoma. Oncology 2002, 63, 378-384.
84. Inoue, T.; Yashiro, M.; Nishimura, S.; Maeda, K.; Sawada, T.; Ogawa, Y.; Sowa, M.; Chung, K. H. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int. J. Mol. Med. 1999, 4, 73-77.
85. Allgayer, H.; Babic, R.; Beyer, B. C.; Grutzner, K. U.; Tarabichi, A.; Schildberg, F. W.; Heiss, M. M. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer. Oncology 1998, 55, 152-160.
86. Sier, C. F.; Kubben, F. J.; Ganesh, S.; Heerding, M. M.; Griffioen, G.; Hanemaaijer, R.; van Krieken, J. H.; Lamers, C. B.; Verspaget, H. W. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br. J. Cancer 1996, 74, 413-417.
87. Elnemr, A.; Yonemura, Y.; Bandou, E.; Kinoshita, K.; Kawamura, T.; Takahashi, S.; Tochiori, S.; Endou, Y.; Sasaki, T. Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer 2003, 6, 30-38.
88. Mori, M.; Mimori, K.; Shiraishi, T.; Fujie, T.; Baba, K.; Kusumoto, H.; Haraguchi, M.; Ueo, H.; Akiyoshi, T. Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int. J. Cancer 1997, 20, 316-321.
89. Kitadai, Y.; Sasaki, A.; Ito, M.; Tanaka, S.; Oue, N.; Yasui, W.; Aihara, M.; Imagawa, K.; Haruma, K.; Chayama, K. Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells. Biochem. Biophys. Res. Comm. 2003, 311, 809-814.
90. www.nhgri.nih.gov
91. Carr, K. M.; Bittner, M.; Trent, J. M. Gene-expression profiling in human cutaneous melanoma. Oncogene 2003, 22, 3076-3080.
92. Väisänen, A.; Kallioinen, M.; Taskinen, P. J.; Turpeenniemi-Hujanen, T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J. Pathol. 1998, 186, 51-58.
93. Nikkola, J.; Vihinen, P.; Vlaykova, T.; Hahka-Kemppinen, M.; Kähäri, V. M.; Pyrhönen, S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int. J. Cancer 2002, 97, 432-438.
94. Vihinen, P. P.; Pyrhönen, S. O.; Kähäri V. M. New prognostic factors and developing therapy of cutaneous melanoma. Ann. Med. 2003, 35, 66-78.
95. Hendrix, M. J. C.; Seftor, E. A.; Hess, A. R.; Seftor, R. E. B. Vascular mimicry and tumour-cell plasticity. Lessons from melanoma. Nat. Rev. Cancer 2003, 3, 411-421.
96. Nikkola, J.; Vihinen, P.; Vuoristo, M. S.; Kellokumpu-Lehtinen, P.; Kähäri, V.M.; Pyrhönen, S. High serum levels of total MMP-9 and MMP-1 are associated with rapid progression in metastatic melanoma. Clin. Cancer Res. 2004, in press.
97. Perez, C. A.; Brady, L. W. In Principles and Practice of Radiation Oncology; Lippincott-Raven Publishers: NY, 1998, pp. 981-1093.
98. O-Charoenrat, P.; Pillai, G.; Patel, S.; Fisher, C.; Archer, D.; Eccles, S.; Rhys-Evans, P. Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral. Oncol. 2003, 39, 386-390.
99. Yoshizaki, T.; Maruyama, Y.; Sato, H.; Furukawa, M. Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int. J. Cancer 2001, 95, 44-50.
100. Yorioka, C. W.; Coletta, R. D.; Alves, F.; Nishimoto, I. N.; Kowalski, L. P.; Graner, E. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int. J. Oncol. 2002, 20, 189-194.
101. O-Charoenrat, P.; Rhys-Evans, P. H.; Eccles, S. A. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2001, 27, 813-820.
102. Myoung, H.; Kim, M. J.; Hong, S. D.; Lee, J. I.; Lim, C. Y.; Hong, S. P. Expression of membrane type I-matrix metalloproteinase in oral squamous cell carcinoma. Cancer Lett. 2002, 185, 201-209.
103. Bogusiewicz, M.; Stryjecka-Zimmer, M.; Szymanski, M.; Rechberger, T.; Golabek, W. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer. Otolaryngol. Head Neck Surg. 2003, 128, 132-136.
104. Katayama, A.; Bandoh, N.; Kishibe, K.; Takahara, M.; Ogino, T.; Nonaka, S.; Harabuchi, Y. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin. Cancer Res. 2004, 10, 634-640.
105. Jiang, X.; Dutton, C. M.; Qi, W.; Block, J. A.; Brodt, P.; Durko, M.; Scully, S. P. Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. J. Orthop. Res. 2003, 27, 1063-1070.
106. Yonemura, Y.; Endo, Y.; Fujita, H.; Kimura, K.; Sugiyama, K.; Momiyama, N.; Shimada, H.; Sasaki, T. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide. J. Exp. Clin. Cancer Res. 2001, 20, 205-212.
107. Hasegawa, S.; Koshikawa, N.; Momiyama, N.; Moriyama, K.; Ichikawa, Y.; Ishikawa, T.; Mitsuhashi, M.; Shimada, H.; Miyazaki, K. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int. J. Cancer 1998, 76, 812-816.
108. London, C. A.; Sekhon, H. S.; Arora, V.; Stein, D. A.; Iversen, P. L.; Devi, G. R. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther. 2003, 10, 823-832.
109. Lakka, S. S.; Rajan, M.; Gondi, C.; Yanamandra, N.; Chandrasekar, N.; Jasti, S. L.; Adachi, Y.; Siddique, K.; Gujrati, M.; Olivero, W.; Dinh, D.H.; Kouraklis, G.; Kyritsis, A. P.; Rao, J. S. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002, 21, 8011-8019.
110. Agarwal, D.; Goodison, S.; Nicholson, B.; Tarin, D.; Urquidi, V. Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation 2003, 71, 114-125.
111. Kondo, M.; Asai, T.; Katanasaka, Y.; Sadzuka, Y.; Tsukada, H.; Ogino, K.; Taki, T.; Baba, K.; Oku, N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer 2004, 108, 301-306.
112. Hua, J.; Muschel, R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 1996, 56, 5279-5284.
113. Ala-aho, R.; Ahonen, M.; George, S. J.; Heikkilä, J.; Grénman, R.; Kallajoki, M.; Kähäri, V. M. Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene 2004, 23, 5111-5123.
114. Vanhecke, D.; Janitz, M. High-throughput gene silencing using cell arrays. Oncogene 2004, 23, 8353-8358.
115. Jiang, X.; Dutton, C. M.; Qi, W. H; Block, J. A.; Garamszegi, N.; Scully, S.P. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J. Cell Physiol. 2005, Mar; 202(3), 723-30.
116. Ho, A. T.; Voura, E. B.; Soloway, P. D.; Watson, K. L.; Khokha, R. MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function. J. Biol. Chem. 2001, 276, 40215-40224.
117. Nelson, A. R.; Fingleton, B.; Rotherberg, M. L.; Matrisian, L. M. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 2000, 18, 1135-1149.
118. Sheikh, M. S.; Huang, Y. Death receptors as targets of cancer therapeutics. Curr. Cancer Drug Targets 2004, 4, 97-104.
119. Beattie, G. J.; Smyth, J. F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin. Cancer Res. 1998, 4, 1899-1902.
120. Kruger, A.; Soeltl, R.; Sopov, I.; Kopitz, C.; Arlt, M.; Magdolen, V.; Harbeck, N.; Gansbacher, B.; Schmitt, M. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res. 2001, 61, 1272-1275.
121. Macaulay, V. M.; O'Byrne, K. J.; Saunders, M. P.; Braybrooke, J. P.; Long, L.; Gleeson, F. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 1999, 5, 513-520.
122. Hidalgo, M.; Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 2001, 93, 178-193.
123. Primrose, J. N.; Bleiberg, H.; Daniel, F.; Van Belle, S.; Mansi, J. L.; Seymour, M.; Johnson, P. W.; Neoptolemos, J. P.; Baillet, M.; Barker, K.; Berrington, A.; Brown, P. D.; Millar, A. W.; Lynch, K. P. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcioembryonic antigen. Br. J. Cancer 1999, 79, 509-514.
124. Rosemurgy, A.; Harris, J.; Langleben, A.; Casper, E.; Goode, S.; Rasmussen, H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol. 1999, 22, 247-252.
125. Evans, J. D.; Stark, A.; Johnson, C. D.; Daniel, F.; Carmichael, J.; Buckels, J.; Imrie, C. W.; Brown, P.; Neoptolemos, J. P. A Phase II trial of marimastat in advanced pancreatic cancer. Br. J. Cancer. 2001, 55, 1865-1870.
126. Miller, K. D.; Gradishar, W.; Schuchter, L.; Sparano, J. A.; Cobleigh, M.; Robert, N.; Rasmussen, H.; Sledge, G. W. A randomized Phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann. Oncol. 2002, 13, 1220-1224.
127. Quirt, I.; Bodurth, A.; Lohmann, R.; Rusthoven, J.; Belanger, K.; Young, V.; Wainman, N.; Stewar, W.; Eisenhauer, E.; National Cancer Institute of Canada Clinical Trials Group. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs 2002, 20, 431-437.
128. Larson, D. A.; Prados, M.; Lamborn, K. R.; Smith, V.; Sneed, P. K.; Chang, S.; Nicholas, K. M.; Wara, W. M.; Devriendt, D.; Kunwar, S.; Berger, M.; McDermott, M. W. Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 2002, 54, 1397-1404.
129. Groves, M. D.; Puduvalli, V. K.; Hess, K. R.; Jaeckle, K. A.; Peterson, P.; Yung, W. K.; Levin, V.A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002, 20, 1383-1388.
130. Bramhall, S. R.; Rosemurgy, A.; Brown, P. D.; Bowry, C.; Buckels, J. A.; Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 2001, 19, 3447-3455.
131. Bramhall, S. R.; Schulz, J.; Nemunaitis, J.; Brown, P. D.; Baillet, M.; Buckels, J. A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002, 87, 161-167.
132. British Biotech plc. Results of marimastat study 186 in patients with advanced ovarian cancer. Press release 2001, May 2.
133. Shepherd, F.A.; Giaccone, G.; Seymour, L.; Debruyne, C.; Bezjak, A.; Hirsh, V.; Smylie, M.; Rubin, S.; Martins, H.; Lamont, A.; Krzakowski, M.; Sadura, A.; Zee, B. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 2002, 20, 4434-4439.
134. Tierney, G. M.; Griffin, N. R.; Stuart, R. C. A pilot study of the safety and effects of the matrix metalloproteinase onhibitor marimastat in gastric cancer. Eur. J. Cancer 1999, 35, 563-568.
135. King, J.; Zhao, J.; Clingan, P.; Morris, D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res. 2003, 23, 639-645.
136. Marimastat. BB 2516, TA 2516. [No authors listed] Drugs R D 1999, 1, 146-149.
137. Wall, L.; Talbot, D. C.; Bradbury, P.; Jodrell, D. I. A Phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumors. Br. J. Cancer 2004, 90, 800-804.
138. Liu, J.; Tsao, M. S.; Pagura, M.; Shalinsky, D. R.; Khoka, R.; Fata, J.; Johnston, M. R. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung Cancer 2003, 42, 335-344.
139. Pfizer Inc. Pfizer discontinues Phase III trials of prinomastat in advanced cancers but continues multiple Phase II trials. Press Release, 2001, August 4.
140. Agouron Pharmaceuticals Inc. Agouron announces pilot Phase II clinical trial of its matrix metalloproteinase inhibitor prinomastat in glioblastoma multiforme. Press Release, 1999, November, 22.
141. Rowinsky, E. K.; Humphrey, R.; Hammond, L. A.; Aylesworth, C.; Smetzer, L.; Hidalgo, M.; Morrow, M.; Smith, L.; Garner, A.; Sorensen, J. M.; Von Hoff, D. D.; Eckhardt, S. G. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. 2000, 18, 178-186.
142. Duivenvoorden, W. C.; Hirte, H. W.; Singh, G. Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 Phase I study. Int. J. Cancer 2001, 91, 857-862.
143. Hirte, H.; Goel, R.; Major, P.; Seymour, L.; Huan, S.; Stewart, D.; Yau, J.; Arnold, A.; Holohan, S.; Waterfield, B.; Bates, S.; Bennett, K.; Walsh, W.; Elias, I. A Phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann. Oncol. 2000, 11, 1579-1584.
144. Moore, M. J.; Hamm, J.; Dancey, J.; Eisenberg, P. D.; Dagenais, M.; Fields, A.; Hagan, K.; Greenberg, B.; Colwell, B.; Zee, B.; Tu, D.; Ottaway, J.; Humphrey, R.; Seymour, L.; National Cancer Institute of Canada Clinical Trials Group. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2003, 21, 3296-3302.
145. Bayer Halts clinical Trials Evaluating MMPI. PR Newswire, 1999, September 24.
146. Ferrante, K.; Winograd, B.; Canetta, R. Promising new developments in cancer chemotherapy. Cancer Chemother. Pharmacol. 1999, 43, S61-S68.
147. Lockhart, A. C.; Braun, R. D.; Yu, D.; Ross, J. R.; Dewhirst, M. W.; Humphrey, J. S.; Thompson, S.; Williams, K. M.; Klitzman, B.; Yuan, F.; Grichnik, J. M.; Proia, A. D.; Conway, D. A.; Hurwitz, H. I. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res. 2003, 9, 586-593.
148. Miller, K. D.; Saphner, T. J.; Waterhouse, D. M.; Chen, T. T.; Rush-Taylor, A.; Sparano, J. A.; Wolff, A. C.; Cobleigh, M. A.; Galbraith, S.; Sledge, G. W. A randomized Phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin. Cancer Res. 2004, 10, 1971-1975.
149. Rizvi, N. A.; Humphrey, J. S.; Ness, E. A.; Johnson, M. D.; Gupta, E.; Williams, K.; Daly, D. J.; Sonnichsen, D.; Conway, D.; Marshall, J.; Hurwitz, H. A Phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin. Cancer Res. 2004, 10, 1963-1970.
150. www.ClinicalTrials.gov.
151. Levitt, N. C.; Eskens, F. A.; O'Byrne, K. J.; Propper, D. J.; Denis, L. J.; Owen, S. J.; Choi, L.; Foekens, J. A.; Wilner, S.; Wood, J. M.; Nakajima, M.; Talbot, D. C.; Steward, W. P.; Harris, A. L.; Verweij, J. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer. Clin. Cancer Res. 2001, 7, 1912-1922.
152. Brown, P. D. Ongoing trials with matrix metalloproteinase inhibitors. Exp. Opin. Invest. Drugs 2000, 9, 2167-2177.
153. Lein, M.; Jung, K.; Ortel, B.; Stephan, C.; Rothaug, W.; Juchem, R.; Johannsen, M.; Deger, S.; Schnorr, D.; Loening, S.; Krell, H. W. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002, 21, 2089-2096.
154. Yamamoto, A.; Yano, S.; Shiraga, M.; Ogawa, H.; Goto, H.; Miki, T.; Zhang, H.; Sone, S. A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int. J. Cancer 2003, 103, 822-828.
155. Muraishi, Y.; Mitani, N.; Fuse, H.; Saiki, I. Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma. Anticancer Res. 2001, 21, 3845-3852.
156. Yamashita, T.; Fujii, M.; Tomita, T.; Ishiguro, R.; Tashiro, M.; Tokumaru, Y.; Imanishi, Y.; Kanke, M.; Ogawa, K.; Kameyama, K.; Otani, Y. The inhibitory effect of matrix metalloproteinase inhibitor ONO-4817 on lymph node metastasis in tongue carcinoma. Anticancer Res. 2003, 23, 2297-2302.
157. Crul, M.; Beerepoot, L. V.; Stokvis, E.; Vermaat, J. S.; Rosing, H.; Beijnen, J. H.; Voest, E. E.; Schellens, J. H. Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518. Cancer Chemother. Pharmacol. 2002, 50, 473-478.
158. Wagenaar-Miller, R. A.; Hanley, G.; Shattuck-Brandt, R.; DuBois, R. N.; Bell, R. L.; Matrisian, L. M.; Morgan, D. W. Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br. J. Cancer 2003, 88, 1445-1452.
159. Shinoda, K.; Shibuya, M.; Hibino, S.; Ono, Y.; Matsuda, K.; Takemura, A.; Zou, D.; Kokubo, Y.; Takechi, A.; Kudoh, S. A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line. Int. J. Oncol. 2003, 22, 281-288.
160. Bukowski, R. M. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Exp. Opin. Investig. Drugs 2003, 12, 1403-1411.
161. Dredge, K. AE-941 (AEterna). Curr. Opin. Invest. Drugs 2004, 5, 668-677.
162. Falardeau, P.; Champagne, P.; Poyet, P.; Hariton, C.; Dupont, E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in Phase III clinical trials. Semin. Oncol. 2001, 28, 620-625.
163. Batist, G.; Patenaude, F.; Champagne, P.; Croteau, D.; Levinton, C.; Hariton, C.; Escudier, B.; Dupont, E. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a Phase II trial with two dose levels. Ann. Oncol. 2002, 13, 1259-1263.
164. Lokeshwar, B. L.; Escatel, E.; Zhu, B. Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3). Curr. Med. Chem. 2001, 8, 271-279.
165. Rudek, M. A.; Figg, W. D.; Dyer, V.; Dahut, W.; Turner, M. L.; Steinberg, S. M.; Liewehr, D. J.; Kohler, D. R.; Pluda, J. M.; Reed, E. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol. 2001, 19, 584-592.
166. Cianfrocca, M.; Cooley, T. P.; Lee, J. Y.; Rudek, M. A.; Scadden, D. T.; Ratner, L.; Pluda, J.M.; Figg, W.D.; Krown, S.E.; Dezube, B.J. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a Phase I AIDS malignancy consortium study. J. Clin. Oncol. 2002, 20, 153-159.
167. Rudek, M. A.; Venitz, J.; Ando, Y.; Reed, E.; Pluda, J. M.; Figg, W. D. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. J. Clin. Pharmacol. 2003, 43, 1124-1135.
168. Rudek, M. A.; Horne, M.; Figg, W. D.; Dahut, W.; Dyer, V.; Pluda, J. M.; Reed, E. Reversible sideroplastic anemia associated with the tetracycline analogue COL-3. Am. J. Hematol. 2001, 67, 51-53.
169. Collagenex Pharmaceuticals, Inc. Press releases 2004, 4, 30.
170. Teronen, O.; Heikkilä, P.; Konttinen, Y. T.; Laitinen, M.; Salo, T.; Hanemaaijer, R.; Teronen, A.; Maisi, P.; Sorsa, T. MMP inhibition and downregulation by biphosphonates. Ann. NY Acad. Sci. 1999, 878, 453-465.
171. Hortobagyi, G. N.; Theriault, R. L.; Porter, L.; Blayney, D.; Lipton, A.; Sinoff, C.; Wheeler, H.; Simeone, J. F.; Seaman, J.; Knight, R. D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 1996, 335, 1785-1791.
172. Brown, J. E.; Neville-Webbe, H.; Coleman, R. E. The role of bisphosphonates in breast and prostate cancers. Endocr. Relat. Cancer 2004, 11, 207-224.
173. Stearns, M. E.; Wang, M. Alendronate blocks metalloproteinase secretion and bone collagen 1 release by PC-3 ML cells in SC1D mice. Clin. Exp. Metastasis 1998, 16, 693-702.
174. Farina, A. R.; Tacconelli, A.; Teti, A.; Gulino, A.; Mackay, A. R. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the biphosphonate alendronate. Cancer Res. 1998, 58, 2957-2960.
175. Paterson, A. H. Adjuvant biphosphonate therapy: the future. Semin. Oncol. 2001, 4S11, 81-85.
176. Ross, J. R.; Saunders, Y.; Edmonds, P. M.; Patel, S.; Wonderling, D.; Normand, C.; Broadley, K. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol. Assess. 2004, 8, 1-176.
177. Mitsiades, N.; Poulaki, V.; Leone, A.; Tsokos, M. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. J. Natl. Cancer Inst. 1999, 91, 1678-1684.
178. Mitsiades, N.; Poulaki, V.; Mitsiades, C. S.; Anderson, K. C. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug. Expert Opin. Investig. Drugs 2001, 10, 1075-1084.
179. Patterson, B. C.; Sang, Q. A. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 1997, 272, 28823-28825.
180. Lijnen, H. R.; Ugwu, F.; Bini, A.; Collen, D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998, 37, 4699-4702.
181. Dong, Z.; Kumar, R.; Yang, X.; Fidler, I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997, 88, 801-810.
182. Reimers, N.; Zafrakas, K.; Assmann, V.; Egen, C.; Riethdorf, L.; Riethdorf, S.; Berger, J.; Ebel, S.; Janicke, F.; Sauter, G.; Pantel, K. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin. Cancer Res. 2004, 10, 3422-3428.
183. Vihinen, P.; Kähäri, V. M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 2002, 99, 157-166.